Published : 2024-02-13

The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health

Adam Piasecki

Magdalena Sitnik

Jakub Olszewski

Maciej Bara

Katarzyna Herjan

Piotr Armański


Finerenone is a novel non-steroidal mineralocorticoid receptor antagonist (MRA) with high selectivity and affinity to mineralocorticoid receptor (MR). Steroidal MRAs, like spironolactone and eplerenone, have been in use for decades. They have an established position in the management of hypertension and heart failure with reduced ejection fraction (HFrEF). There are studies showing that MR antagonism has anti-inflammatory and anti-fibrotic effects resulting in cardiovascular and renal protection. However, broader use of steroidal MRAs is seriously limited by antiandrogenic side effects and the risk of hyperkalemia. The differences in structure as well as pharmacokinetic and pharmacodynamic properties between steroidal and non-steroidal MRAs result in reduced risk of side effects while offering the benefit of cardiorenal protection. Finerenone is currently the only non-steroidal MRA approved by European Medicines Agency (EMA). It is indicated for patients with chronic kidney disease (CKD) with albuminuria and type 2 diabetes mellitus (DM2). Several studies showed a reduction of the risk of cardiovascular and renal events in this group of patients compared to placebo. The risk of hyperkalemia was increased resulting in discontinuation of treatment in more patients than placebo, but the risk of serious adverse events did not differ significantly. The other indications for finerenone, including heart failure (HF) management, are currently being researched.


chronic kidney disease, finerenone, heart failure, mineralocorticoid receptor antagonists, cardiorenal protection





Download files


Citation rules

Piasecki, A., Sitnik, M., Olszewski, J., Bara, M., Herjan, K., & Armański, P. (2024). The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health. Prospects in Pharmaceutical Sciences, 22(1), 11–15.

Altmetric indicators

Cited by / Share


Editorial Team
Stefana Banacha 1
02-097 Warsaw, Poland
Medical University of Warsaw
ul. Żwirki i Wigury 61
02-091 Warszawa

Copyright 2021 by
OJS Support and Customization by LIBCOM
Platform & workfow by OJS/PKP